Sanofi Genzyme Competitors and Similar CompaniesClear all
Biogen's competitors and similar companies include Amgen, Amicus Therapeutics and Gero.
 Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases. |  Gero Gero is a biotechnology company intended to evaluate the personal risks of mortality and health. | |
Founding Date | Founding Date 1978 | Founding Date 1980 | Founding Date 2002 | Founding Date 2015 |
Type | Type Public | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Philadelphia, US HQ Northbridge, AU Pointe Claire, CA Paris, FR München, DE Dublin, IE Milano, IT see more | Locations Singapore, SG HQ Agios Athanasios, CY Moskva, RU |
Employees | Employees 7,605 | Employees 25,200 | Employees 58415% increase | Employees 105 |
Valuation ($) | Valuation ($) 26.7 b | Valuation ($) 170.4 b | Valuation ($) 3.4 b | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) $9.9b (FY, 2025) | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) $634.2m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods $2.4b (FY, 2025) | Cost of goods $12b (FY, 2025) | Cost of goods $72.9m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $7.5b (FY, 2025) | Gross profit $24.7b (FY, 2025) | Gross profit $561.3m (FY, 2025) | Gross profit N/A |
Net income | Net income $1.3b (FY, 2025) | Net income $7.7b (FY, 2025) | Net income ($27.1m) (FY, 2025) | Net income N/A |
Operating ⚠ | ||||
Phase I Trials Products | Phase I Trials Products 4 (FY, 2024) | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 6 (FY, 2024) | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 11 (FY, 2024) | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 88m | Total funding raised $ 7.5m |
For sources of this data, please see the company profile
View Company Profiles
Amgen
HQ
Thousand Oaks, US
Employees
25,200
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
View companyAmicus Therapeutics
HQ
Philadelphia, US
Employees
584↑ 15% increase
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
View companyGero
HQ
Singapore, SG
Employees
105
Gero is a biotechnology company intended to evaluate the personal risks of mortality and health.
View company